WO2019005817A3 - Hybridoma clones, monoclonal antibodies to vsig-4, and methods of making and using - Google Patents

Hybridoma clones, monoclonal antibodies to vsig-4, and methods of making and using

Info

Publication number
WO2019005817A3
WO2019005817A3 PCT/US2018/039532 US2018039532W WO2019005817A3 WO 2019005817 A3 WO2019005817 A3 WO 2019005817A3 US 2018039532 W US2018039532 W US 2018039532W WO 2019005817 A3 WO2019005817 A3 WO 2019005817A3
Authority
WO
WIPO (PCT)
Prior art keywords
vsig
monoclonal antibodies
making
methods
hybridoma clones
Prior art date
Application number
PCT/US2018/039532
Other languages
French (fr)
Other versions
WO2019005817A2 (en
Inventor
Birte Aggeler
Christine Goetz
Jody Bonnevier
Christopher Carlin VALLEY
Chris Hammerbeck
Ernesto Ruben RESNIK
Original Assignee
Bio-Techne Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio-Techne Corporation filed Critical Bio-Techne Corporation
Priority to CN201880042300.2A priority Critical patent/CN110944666A/en
Priority to EP18824284.6A priority patent/EP3645042A4/en
Publication of WO2019005817A2 publication Critical patent/WO2019005817A2/en
Publication of WO2019005817A3 publication Critical patent/WO2019005817A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Described herein are monoclonal antibodies that bind to VSIG-4 including antibodies that block the binding of VSIG-4 to SIGLEC-7, compositions including the monoclonal antibodies, and methods of making and using those antibodies and compositions.
PCT/US2018/039532 2017-06-26 2018-06-26 Hybridoma clones, monoclonal antibodies to vsig-4, and methods of making and using WO2019005817A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201880042300.2A CN110944666A (en) 2017-06-26 2018-06-26 Monoclonal antibodies to hybridoma clones, VSIG-4, and methods of making and using
EP18824284.6A EP3645042A4 (en) 2017-06-26 2018-06-26 Hybridoma clones, monoclonal antibodies to vsig-4, and methods of making and using

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762524821P 2017-06-26 2017-06-26
US62/524,821 2017-06-26

Publications (2)

Publication Number Publication Date
WO2019005817A2 WO2019005817A2 (en) 2019-01-03
WO2019005817A3 true WO2019005817A3 (en) 2019-05-02

Family

ID=64691960

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/039532 WO2019005817A2 (en) 2017-06-26 2018-06-26 Hybridoma clones, monoclonal antibodies to vsig-4, and methods of making and using

Country Status (4)

Country Link
US (2) US10752689B2 (en)
EP (1) EP3645042A4 (en)
CN (1) CN110944666A (en)
WO (1) WO2019005817A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2994822C (en) 2015-08-07 2023-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Near infrared photoimmunotherapy (nir-pit) of suppressor cells to treat cancer
WO2019005817A2 (en) 2017-06-26 2019-01-03 Bio-Techne Corporation Hybridoma clones, monoclonal antibodies to vsig-4, and methods of making and using
CN113423728B (en) 2018-09-28 2024-03-01 优特力克斯有限公司 Anti-human VSIG4 antibodies and uses thereof
US20220306736A1 (en) * 2019-09-04 2022-09-29 Y-Biologics Inc. Anti-vsig4 antibody or antigen binding fragment and uses thereof
CN111574627A (en) * 2020-05-11 2020-08-25 潘宗富 anti-VSIG4 monoclonal antibodies and uses thereof
KR20230156727A (en) 2021-03-03 2023-11-14 피에르 파브르 메디카먼트 Anti-VSIG4 antibody or antigen-binding fragment thereof and uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106188298A (en) * 2016-07-27 2016-12-07 西安交通大学 A kind of Vsig4 nano antibody and epitope authentication method thereof and application

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
WO1990002809A1 (en) 1988-09-02 1990-03-22 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
JP4146512B2 (en) 1991-03-01 2008-09-10 ダイアックス コープ． Small protein
DK1471142T3 (en) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimeric receptor libraries using phagemids
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
CA2682835A1 (en) * 2007-05-01 2008-11-13 Genentech, Inc. Crig antagonists
AU2010282340B2 (en) * 2009-08-13 2016-12-22 The Johns Hopkins University Methods of modulating immune function
KR101730868B1 (en) * 2013-09-13 2017-04-27 인제대학교 산학협력단 Pharmaceutical composition comprising VSIG4 inhibitor for preventing or treating ovarian cancer
CN105924515B (en) * 2016-04-25 2019-06-14 中国人民解放军第三军医大学 Co-stimulators VSIG4 activity epitope peptide, monoclonal antibody and its preparation method and application
WO2019005817A2 (en) 2017-06-26 2019-01-03 Bio-Techne Corporation Hybridoma clones, monoclonal antibodies to vsig-4, and methods of making and using

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106188298A (en) * 2016-07-27 2016-12-07 西安交通大学 A kind of Vsig4 nano antibody and epitope authentication method thereof and application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM ET AL.: "Extracellular stimulation of VSIG4/complement receptor Ig suppresses intracellular bacterial infection by inducing autophagy", AUTOPHAGY, vol. 12, no. 9, 2016, pages 1647 - 1659, XP055596956 *

Also Published As

Publication number Publication date
US11897958B2 (en) 2024-02-13
US20180371095A1 (en) 2018-12-27
EP3645042A4 (en) 2021-03-17
CN110944666A (en) 2020-03-31
WO2019005817A2 (en) 2019-01-03
US20210087276A1 (en) 2021-03-25
EP3645042A2 (en) 2020-05-06
US10752689B2 (en) 2020-08-25

Similar Documents

Publication Publication Date Title
WO2020039321A8 (en) Anti-gdf15 antibodies, compositions and methods of use
WO2019005817A3 (en) Hybridoma clones, monoclonal antibodies to vsig-4, and methods of making and using
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
WO2017184619A3 (en) Agonistic antibodies that bind human cd40 and uses thereof
MX2018008934A (en) Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same.
MX2022011002A (en) Humanized or chimeric cd3 antibodies.
WO2016014688A3 (en) Anti-pd-1 antibodies
WO2018217940A3 (en) Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
WO2017079116A3 (en) Antibodies specifically binding pd-1 and tim-3 and their uses
WO2015127136A3 (en) Ebola monoclonal antibodies
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
WO2017136562A3 (en) Bispecific binding proteins for pd-l1 and kdr
PH12020500667A1 (en) Multispecific antibodies and use thereof
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2022015258A (en) Anti-cxcr5 antibodies and compositions and uses thereof.
WO2017021539A3 (en) Novel anti-human gpvi antibodies and uses thereof
WO2021022304A3 (en) Bispecific anti lrrc15 and cd3epsilon antibodies
MX2019009498A (en) Fgf21 mimetic antibodies and uses thereof.
IL288727A (en) Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
EP3904387A4 (en) Monoclonal antibodies that bind specifically to human trbv9
WO2018227063A8 (en) Anti-robo2 antibodies, compositions, methods and uses thereof
IL287809A (en) Anti-bcma antibody conjugate, compositions comprising the same, and methods of making and using the same
IL285489A (en) Producing compositions comprising two or more antibodies
EP3710482A4 (en) Compositions and methods for making and using bispecific antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18824284

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18824284

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2018824284

Country of ref document: EP

Effective date: 20200127